105 related articles for article (PubMed ID: 12682642)
1. Intramuscular edema as a complication of treatment with imatinib.
Shimazaki C; Ochiai N; Uchida R; Fuchida SI; Okano A; Ashihara E; Inaba T; Fujita N; Nakagawa M
Leukemia; 2003 Apr; 17(4):804-5. PubMed ID: 12682642
[No Abstract] [Full Text] [Related]
2. G-CSF for imatinib-induced neutropenia.
Heim D; Ebnöther M; Meyer-Monard S; Tsakiris D; Linn M; Tichelli A; Gratwohl A
Leukemia; 2003 Apr; 17(4):805-7. PubMed ID: 12682643
[No Abstract] [Full Text] [Related]
3. Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec).
Gordon JK; Magid SK; Maki RG; Fleisher M; Berman E
Leuk Res; 2010 Jun; 34(6):827-9. PubMed ID: 19963273
[TBL] [Abstract][Full Text] [Related]
4. Practical management of patients with chronic myeloid leukemia receiving imatinib.
Deininger MW; O'Brien SG; Ford JM; Druker BJ
J Clin Oncol; 2003 Apr; 21(8):1637-47. PubMed ID: 12668652
[TBL] [Abstract][Full Text] [Related]
5. Ocular side effects in chronic myeloid leukemia patients treated with imatinib.
Breccia M; Gentilini F; Cannella L; Latagliata R; Carmosino I; Frustaci A; Alimena G
Leuk Res; 2008 Jul; 32(7):1022-5. PubMed ID: 18061664
[TBL] [Abstract][Full Text] [Related]
6. Gleevec: tailoring to fit.
May TS
Drug Discov Today; 2003 Mar; 8(5):188-9. PubMed ID: 12634004
[No Abstract] [Full Text] [Related]
7. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
[TBL] [Abstract][Full Text] [Related]
8. Cardiotoxicity of imatinib: At the heart of the problem.
Tiribelli M; Medeot M
Leuk Res; 2011 Jan; 35(1):36-7. PubMed ID: 20970188
[No Abstract] [Full Text] [Related]
9. Are there new clinical parameters useful to predict response in chronic myeloid leukemia in the imatinib era?
Breccia M; Alimena G
Leuk Res; 2009 Nov; 33(11):1450-1. PubMed ID: 19615745
[No Abstract] [Full Text] [Related]
10. [Management of chronic myeloid leukemia by imatinib].
Kizaki M
Rinsho Ketsueki; 2010 Oct; 51(10):1377-85. PubMed ID: 20962470
[No Abstract] [Full Text] [Related]
11. Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate.
Garipidou V; Vakalopoulou S; Tziomalos K
Oncologist; 2005; 10(6):457-8. PubMed ID: 15967839
[No Abstract] [Full Text] [Related]
12. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate.
Schoch C; Haferlach T; Kern W; Schnittger S; Berger U; Hehlmann R; Hiddemann W; Hochhaus A
Leukemia; 2003 Feb; 17(2):461-3. PubMed ID: 12592348
[No Abstract] [Full Text] [Related]
13. Unusual fluid retention with imatinib therapy for chronic myeloid leukemia.
Ostro D; Lipton J
Leuk Lymphoma; 2007 Jan; 48(1):195-6. PubMed ID: 17325868
[No Abstract] [Full Text] [Related]
14. Oral melanosis after tyrosine kinase inhibition with Imatinib for chronic myelogenous leukemia: report of a case and review of the literature.
Wong M; Sade S; Gilbert M; Klieb HB
Dermatol Online J; 2011 May; 17(5):4. PubMed ID: 21635826
[TBL] [Abstract][Full Text] [Related]
15. Peripheral neuropathy as an adverse effect of imatinib therapy.
Chakupurakal G; Etti RJ; Murray JA
J Clin Pathol; 2011 May; 64(5):456. PubMed ID: 21278395
[No Abstract] [Full Text] [Related]
16. Safe treatment of a patient with CML using dasatinib after prior retinal oedema due to imatinib.
Bajel A; Bassili S; Seymour JF
Leuk Res; 2008 Nov; 32(11):1789-90. PubMed ID: 18462793
[No Abstract] [Full Text] [Related]
17. Imatinib-associated hyperpigmentation, a side effect that should be recognized.
Mcpherson T; Sherman V; Turner R
J Eur Acad Dermatol Venereol; 2009 Jan; 23(1):82-3. PubMed ID: 18384557
[No Abstract] [Full Text] [Related]
18. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).
Hochhaus A
Ann Hematol; 2004; 83 Suppl 1():S65-6. PubMed ID: 15124676
[No Abstract] [Full Text] [Related]
20. Pure red cell aplasia in a patient of chronic granulocyte leukemia associated with imatinib.
Meng HT; Li Y; Jin J; Qian WB; Yang CM
Ann Hematol; 2007 Mar; 86(3):231-2. PubMed ID: 17123082
[No Abstract] [Full Text] [Related]
[Next] [New Search]
